HERBERT J. CONRAD - 19 Jun 2021 Form 4 Insider Report for Matinas BioPharma Holdings, Inc. (MTNB)

Role
Director
Signature
/s/ Keith A. Kucinski, attorney-in fact for Herbert J. Conrad
Issuer symbol
MTNB
Transactions as of
19 Jun 2021
Net transactions value
$0
Form type
4
Filing time
24 Jun 2021, 17:37:54 UTC
Previous filing
21 Jun 2021
Next filing
09 Jul 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MTNB Common Stock, par value $0.0001 per share Other $0 +40,000 +3% $0.000000 1,360,905 19 Jun 2021 By Herbert J. Conrad Trust u/a/d 3/4/2005, Herbert J Conrad, Susan Wachtel, Nancy Fallick, Trustees F1
transaction MTNB Common Stock, par value $0.0001 per share Conversion of derivative security $0 +200,000 +15% $0.000000 1,560,905 19 Jun 2021 By Herbert J. Conrad Trust u/a/d 3/4/2005, Herbert J Conrad, Susan Wachtel, Nancy Fallick, Trustees F2
holding MTNB Common Stock, par value $0.0001 per share 2,639,039 19 Jun 2021 By Herbert Conrad 2020 Grantor Retained Annuity Trust (GRAT)
holding MTNB Common Stock, par value $0.0001 per share 494,622 19 Jun 2021 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MTNB Series B Preferred Stock Conversion of derivative security $0 -100 -100% $0.000000* 0 19 Jun 2021 Common Stock 200,000 $0.5000 By Herbert J. Conrad Trust u/a/d 3/4/2005, Herbert J Conrad, Susan Wachtel, Nancy Fallick, Trustees F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Stock dividend, payable to all holders of record of Series B Preferred Stock of 400 shares of Common Stock for each share of Series B Preferred Stock.
F2 On June 19, 2021, pursuant to the Certificate of Designations of Preferences, Rights and Limitations of the Series B Preferred Stock (the "Certificate") of the Issuer, all shares of Series B Convertible Preferred Stock were mandatorily converted into shares of the Issuer's common stock. Each share of Series B Convertible Preferred Stock converted into 2,000 shares of the Issuer's common stock. The shares of Series B Convertible Preferred Stock were convertible at any time, at the holder's election, or upon certain mandatory conversion events set forth in the Certificate. The Series B Convertible Preferred Stock had no expiration date.